Kramer will lead the company’s expanding global rollout of innovation in genetic improvement, particularly in commercial-scale genome editing for aquaculture.
According to CAT, he brings more than two decades of experience driving commercial growth in genomics and various life sciences sectors, with a specialty in commercialising innovation in the genomics field.
He joins CAT following senior roles at QIAGEN, ThermoFisher, Element Biosciences, and Psomagen, where he led transformative sales initiatives, built high-performing teams, and established strategic, value-based partnerships. His expertise spans the commercial spectrum of sales, marketing, and product management, anchored in a strong foundation in genomics, molecular diagnostics, and next generation sequencing technologies.
Commenting on his appointment, Kramer stated in a press release: “I was drawn to this role for its combination of strategic scope and purpose – with the opportunity to help shape how genomic and genome-editing technologies transition from research tools into real-world impact. CAT’s culture, scientific and aquaculture industry expertise, and long-term vision align strongly with my own values as a leader. I’m particularly looking forward to bringing the benefits of genome editing into the aquaculture market and delivering responsible, science-based adoption worldwide.
“Genome editing offers transformative benefits for the global aquaculture industry by enabling targeted genetic improvements that enhance operational productivity, resilience and sustainability, as complementary methods to traditional selective breeding strategies. My passion has always been to work for companies that drive innovation, and CAT provides exactly that opportunity. As the global population grows, CAT’s genome editing services offer a safe, efficient, and effective way to increase the availability of nutritious food while reducing pressure on wild fish stocks.”
Dr John Buchanan, CEO of CAT, added: “We are pleased to have Matt join our team. His experience and leadership will be instrumental as we expand the commercialization of genome editing in aquaculture globally. I look forward to introducing him to our clients and am confident that, together with the rest of our team, we will lead CAT into an exciting new era – further driving innovation, boosting productivity and sustainability, and supporting our core mission of feeding people responsibly.”
